Effect of Statin Therapy on Mortality in Patients With Peripheral Arterial Disease and Comparison of Those With Versus Without Associated Chronic Obstructive Pulmonary Disease

American Journal of Cardiology

Volumn 102, Issue 2, 2008, Pages 192-196

  van Gestel, Yvette R B M ^a   Hoeks, Sanne E ^a   Sin, Don D ^b   Simsek, Cihan ^a   Welten, Gijs M J M ^a   Schouten, Olaf ^a   Stam, Henk ^a   Mertens, Frans W ^a   van Domburg, Ron T ^a   Poldermans, Don ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HUMAN; INFLAMMATION; LOW DRUG DOSE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; VASCULAR SURGERY;

AGED; ANTICHOLESTEREMIC AGENTS; ENDPOINT DETERMINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; POSTOPERATIVE PERIOD; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 46349098873     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.03.038     Document Type: Article

References (15)

1. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., Fukuchi Y., Jenkins C., Rodriguez-Roisin R., van Weel C., and Zielinski J. Global strategy for the diagnosis, management, and prevention of COPD-2006 update. Am J Respir Crit Care Med (2007)
2. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J Suppl 16 (1993) 5-40
3. Subbarao P., Lebecque P., Corey M., and Coates A.L. Comparison of spirometric reference values. Pediatr Pulmonol 37 (2004) 515-522
4. Collins R., Armitage J., Parish S., Sleigh P., Peto R., and Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
5. Feringa H.H., Karagiannis S.E., van Waning V.H., Boersma E., Schouten O., Bax J.J., and Poldermans D. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg 45 (2007) 936-943
6. Poldermans D., Bax J.J., Kertai M.D., Krenning B., Westerhout C.M., Schinkel A.F., Thomson I.R., Lansberg P.J., Fleisher L.A., Klein J., et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 107 (2003) 1848-1851
7. Schillinger M., Exner M., Mlekusch W., Amighi J., Sabeti S., Muellner M., Rumpold H., Wagner O., and Minar E. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 25 (2004) 742-748
8. Soyseth V., Brekke P.H., Smith P., and Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 29 (2007) 279-283
9. Mancini G.B., Etminan M., Zhang B., Levesque L.E., FitzGerald J.M., and Brophy J.M. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47 (2006) 2554-2560
10. Ishida W., Kajiwara T., Ishii M., Fujiwara F., Taneichi H., Takebe N., Takahashi K., Kaneko Y., Segawa I., Inoue H., and Satoh J. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med 212 (2007) 265-273
11. Frost F.J., Petersen H., Tollestrup K., and Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 131 (2007) 1006-1012
12. Ray K.K., Cannon C.P., McCabe C.H., Cairns R., Tonkin A.M., Sacks F.M., Jackson G., and Braunwald E. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 (2005) 1405-1410
13. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., Crowe T., Howard G., Cooper C.J., Brodie B., Grines C.L., and DeMaria A.N. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
14. Jacobson J.R., Barnard J.W., Grigoryev D.N., Ma S.F., Tuder R.M., and Garcia J.G. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 288 (2005) L1026-L1032
15. Fessler M.B., Young S.K., Jeyaseelan S., Lieber J.G., Arndt P.G., Nick J.A., and Worthen G.S. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 171 (2005) 606-615